Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov-Dec;36(7):1678-1682.
doi: 10.12669/pjms.36.7.2620.

Effectiveness of a patient-specific 3-dimensional printed model in Septal Myectomy of hypertrophic cardiomyopathy

Affiliations

Effectiveness of a patient-specific 3-dimensional printed model in Septal Myectomy of hypertrophic cardiomyopathy

Yang Wang et al. Pak J Med Sci. 2020 Nov-Dec.

Abstract

Objective: Advanced cardiovascular surgery in structural heart disease require accurate pre-operative evaluation. Most of non-invasive imaging technologies remain limited in two-dimensional and show insufficiency of visualization for procedural planning. The aim of this study was to discuss the value of patient-specific 3-dimensional (3D) printing in treatment of hypertrophic cardiomyopathy (HCM).

Methods: Patient-specific 3D-printed models were constructed preoperatively in 12 consecutive HOCM patients which come to Beijing Anzhen Hospital for surgical treatment from October 2016 to March 2017. Image files were extracted from multi-slice computed tomography images, 3D models were constructed by the Mimics 19.0 software and generated by Objet350 Connex3 3D printer. The 3D-printed models were made with soft material that can be surgically performed. The modified Morrow myectomy of the model was performed before the operation. Clinical characters and echocardiographic parameters were recorded.

Results: There was no significant difference in tissue volume between the models and specimens. Preoperative and postoperative echocardiography showed the septal thickness was reduced from 18.8±4.5 mm to 12.7±3.3 mm (p<0.001), the left ventricular outflow tract obstruction was adequately relieved (83.0±27.73 mm Hg to 8.7±6.5 mm Hg, p<0.001), and the SAM disappeared completely after the operation. Cardiac function was improved in all patients (New York Heart Association functional class III to class I/II).

Conclusions: The proposed optimal 3D-modelled septal myectomy allows intraoperative monitoring of the shape and volume of the myocardium resection to achieve the 'ideal' interventricular septum. It eliminates obstruction in the LVOT and SAM, resulting in LV remodeling with an increase in LV end-diastolic volume and diameter at early follow-up.

Keywords: 3D printing; Heart model; Hypertrophic cardiomyopathy; Myectomy.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interest: The authors declare that there is no conflict of interest. Conflicts of interest: None.

Figures

Fig.1
Fig.1
Photograph in the operating room of the 3-dimensional print and its myectomy specimens next to the actual myectomy specimen from same patient for comparison from the first patient. A) Photograph of a 3-dimensional print before operative rehearsal. B) The 3-dimensional specimens of 3-dimensional print. C) Photograph of the 3-dimensional print during operative rehearsal. D) The actual myectomy specimen from same patient.
Fig.2
Fig.2
Photograph in the operating room of the 3-dimensional print and its myectomy specimens next to the actual myectomy specimen from same patient for comparison from the second patient. A) Photograph of a 3-dimensional print before operative rehearsal. B) The 3-dimensional specimens of 3-dimensional print. C) Photograph of the 3-dimensional print after operative rehearsal. D) The actual myectomy specimen from same patient.

Similar articles

Cited by

References

    1. American College of Cardiology Foundation/American Heart Association Task Force on P, American Association for Thoracic S, American Society of E, American Society of Nuclear C, Heart Failure Society of A, Heart Rhythm S, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2011;142(6):e153–203. doi:10.1016/j.jtcvs.2011.10.020. - PubMed
    1. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017;136(25):2420–2436. doi:10.1161/CIRCULATIONAHA.117.029267. - PubMed
    1. Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy:A Test in Context. J Am Coll Cardiol. 2016;67(15):1846–1858. doi:10.1016/j.jacc.2016.01.071. - PubMed
    1. Authors/Task Force m. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J. 2014;35(39):2733–2779. doi:10.1093/eurheartj/ehu284. - PubMed
    1. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy:present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83–99. doi:10.1016/j.jacc.2014.05.003. - PubMed

LinkOut - more resources